Journal of Thrombosis and Haemostasis

publication venue for

The Khorana score for the prediction of venous thromboembolism in patients with solid cancer: an individual patient data meta-analysis 2017
Assessment of low molecular weight heparin accumulation in patients with chronic kidney disease: results from the TRIVET study 2016
Cancer, Chronic Kidney Disease and Thrombosis 2016
Comparison of locally measured activated partial thromboplastin time (aPTT) to central laboratory aPTT when measuring reversal of dabigatran using idarucizumab 2016
Efficacy and safety of dabigatran vs. warfarin for the treatment of acute venous thromboembolism: a pooled analysis of 90-day data from RE-COVER (TM) and RE-COVER (TM) II 2016
Safety and efficacy of dabigatran compared with warfarin in patients with acute venous thromboembolism enrolled in RE-COVER (R)/RE-COVER II (TM) in Western Europe 2016
The patient reported outcome burdens and experiences (PROBE) study - phase 1 results show PROBE study methodology feasible 2016
Warfarin dose assessment every 4 weeks vs. every 6 to 8 weeks in patients with stable international normalized ratios: a retrospective study 2016
A Canadian consensus on venous thromboembolism (VTE) prophylaxis prevention in thoracic surgery, a national Delphi consensus survey 2015
A Cross-sectional registry on the incidence of gastrointestinal associated symptoms with pradaxa use (Gasp Registry) 2015
A global prospective cohort study of dabigatran for the treatment of venous thromboembolism (re-covery) 2015
A novel substrate for use in a point of care thrombin generation assay 2015
A population approach to hemophilia pharmacokinetics. Wapps: a web-service for bayesian post hoc estimation 2015
ANNEXA (TM)-A PART 2: A phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet ALFA (PRT064445), a universal antidote for factor XA (FXA) inhibitors 2015
Accuracy of three clinical prediction tools for major bleeding in patients on extended oral anticoagulant for venous thromboembolism 2015
Active thrombin assay for improved treatment of thrombosis 2015
Adherence to anticoagulant treatment with dabigatran and rivaroxaban in a real-world setting 2015
An open-label study of dabigatran pharmacokinetics and pharmacodynamics in patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery 2015
Antithrombotic treatment and outcomes of cirrhotic patients with splanchnic vein thrombosis: a sub-study from the ISTH registry 2015
Antithrombotic treatment and outcomes of non-malignant non-cirrhotic splanchnic vein thrombosis: a sub-analysis from the isth registry 2015
Apixaban for treatment of venous thromboembolism in patients from study centres in Asia; a subgroup analysis of the amplify trial 2015
Arterial thrombosis is accelerated in histidine-rich glycoprotein deficient mice 2015
Assessing the indication and success of treatment for haemophilia patients: results from a delphi panel 2015
Bayesian approach to the assessment of the population specific risk of inhibitors 2015
Between a rock and a hard place: conundrums in the management of cerebral sinovenous thrombosis (CSVT) in children with acute lymphoblastic leukemia (ALL)/lymphoma 2015
Bleeding and thromboembolic outcomes in warfarin-and dabigatran-treated patients in the RE-LY trial who required an urgent surgery or procedure 2015
Bridging anticoagulation in patients who require temporary interruption of warfarin therapy for an elective invasive procedure or surgery (the bridge trial) 2015
Cell-Free DNA modulates clot structure and impairs fibrinolysis in sepsis 2015
Characteristics and reversal strategies of real-world anticoagulation-related hemorrhage in the non-vitamin K antagonist oral anticoagulant era: preliminary data from a multicentre chart review 2015
Clinical presentation and extent of clinical care of clinically relevant non-major bleeding events with apixaban and warfarin 2015
Clinical presentation, impact and course of major bleeding events with apixaban and warfarin 2015
Comparing FEIBA with recombinant FVIIA for reversal of rivaroxaban with a modified anti-Xa assay in undiluted Plasma 2015
Comparison of factor IX glycosylation in different age groups 2015
Comparison of the effect of dabigatran and warfarin on mechanical heart valve-induced thrombin generation 2015
Correlation between deep vein thrombosis and pulmonary embolism using an in vivo mouse model of venous thromboembolism: effect of thrombin inhibition 2015
DNA and RNA activate the contact pathway of coagulation by promoting reciprocal activation of factor XII and prekallikrein 2015
Dabigatran and rivaroxaban adherence study- real world experience in different clinics and extended follow up (dariva study) 2015
Dabigatran or warfarin in the treatment of acute venous thromboembolism in antiphospholipid syndrome 2015
Determinants of inhibitor development in previously treated hemophilia A patients 2015
Development and validation of a Java-based computer program for image analysis of fibrin ultrastructure 2015
Development of a rivaroxaban dosing regimen for treatment of VTE in children aged 12 to 18 years 2015
Direct Oral Anticoagulants in the Real World: Insights into Canadian Health Care Providers’ Understanding of Medication Dosing and Use 2015
Direct-acting oral anticoagulants in the real world: insights into appropriate prescribing and medication use 2015
Discordance between activated partial thromboplastin time and heparin level measured with anti-Xa assay in antithrombin-deficient plasma 2015
Do preterm infants with patent ductus arteriosus (PDA) who fail indomethacin treatment have lower platelet counts?: a systematic review and meta-analysis 2015
Effect of Quebec platelet disorder on leukocyte urokinase plasminogen activator (uPA) levels 2015
Efficacy, pharmacokinetics (PK) and safety results of a phase 3 clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated children with hemophilia B 2015
Engagement of the active site of thrombin by dabigatran or argatroban modulates its exosite-mediated interactions with fibrin and factor VA 2015
Examining the hexosamine biosynthesis pathway in hyperglycemia-induced accelerated atherosclerosis 2015
Exosite interactions uncover a broad substrate recognition profile for ADAMTS13 2015
Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates 2015
Feasibility of comparing intermittent pneumatic compression vs. a novel device for prevention of venous thromboembolism in trauma patients with contraindication to anticoagulation 2015
Hemizygous deletion of 7Q11.21-Q11.23 eliminating VKORC1L1 does not impair blood coagulation but reveals accumulation of menaquinone-4 2015
Hemodialysis for the treatment of dabigatran-associated bleeding: a systematic review of the literature 2015
Higher or lower dose corticosteroids for primary immune thrombocytopenia: systematic review and meta-analysis 2015
Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic pathway of coagulation 2015
Hyperglycaemic apolipoprotein-E deficient mice have accelerated atherosclerosis and aberrant vasa vasorum neovascularization 2015
Identification of alpha-1 proteinase inhibitor variants with enhanced specificity for activated factor XI over thrombin via combined phage display and bacterial lysate screening 2015
Impact of PCSK9 in a murine mouse model of sepsis 2015
Impact of inherited and acquired prothrombotic defects (PD) on the development of symptomatic thromboembolism (STE) in children with acute lymphoblastic leukemia (ALL) treated according to the Dana-Farber Cancer Institute (DFCI) 05-01 All-Therapy Protocol 2015
Impact of the endothelial protein C receptor in coagulation, inflammation and hematopoiesis 2015
Increasing platelets and other measures enhancing hemostasis are both important to prevent bleeding episodes when thrombocytopenic patients requiring antithrombotic therapy - a review of the medical literature 2015
Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products 2015
Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products 2015
Inhibition of fibrinolysis by heparin, low molecular weight heparin and a novel anticoagulant, antithrombin-heparin covalent complex (ATH) 2015
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions 2015
Interventions to reduce blood loss from laboratory testing in critically ill patients and impact on transfusion: a systematic review 2015
Intracranial bleeding with the new oral anticoagulant drugs 2015
Intrinsic and extrinsic coagulation pathways both contribute to ligation-induced deep vein thrombosis in rats 2015
Investigating potential determinants of ITI success using immune gene expression profiling: a preliminary study 2015
Is post thrombotic syndrome perceived to be a clinically relevant outcome?: A survey of physician priorities 2015
Localization of ZN2+in dense granules of human platelets and the extent of its release upon platelet activation 2015
Low dose rivaroxaban for secondary prophylaxis after full anticoagulation in patients with venous thromboembolism 2015
Lysine residues 42, 43, and 44 of thrombin activable fibrinolysis inhibitor contribute to its activation by the thrombin-thrombomodulin complex in a cooperative fashion 2015
Molecular modeling of a novel mutation in the SERPINC1 gene associated with type 1 antithrombin deficiency 2015
Natural history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: findings from the ISTH registry 2015
Net clinical benefit of dabigatran versus warfarin in prevention of recurrent venous thromboembolism: a pooled analysis of re-cover and re-cover II 2015
No beneficial effect of statins in reducing recurrent disease in a meta-analysis of 21,587 patients with acute symptomatic venous thromboembolism treated in phase 3 trials comparing direct oral anticoagulants with vitamin K antagonists 2015
Noacs in venous thromboembolism - strengths and caveats 2015
Occurence and predictors of recurrence within 3 years after a first episode of acute venous thromboembolism: Worcester Venous Thromboembolism Study 2015
Optimal timing of warfarin resumption after warfarin related upper gastrointestinal bleeding 2015
Over-representation of severe subclavian vein occlusion in the affected arm, compared with the contralateral arm, in patients with unprovoked unilateral upper extremity deep vein thrombosis 2015
Perioperative management of dabigatran: a prospective cohort study 2015
Pharmacokinetic characteristics of factor VIII and IX concentrates - a systematic review 2015
Practice variation in the treatment of DVT and prevention of post thrombotic syndrome between internists and vascular surgeons: a Canadian survey of physician practices 2015
Procoagulant effects of lung cancer chemotherapy through release of microparticles and cell-free DNA 2015
Proteolytic inactivation of coagulation factor V by OmpT from enterohemorrhagic Escherichia coli 2015
Quality of vitamin k antagonist control and 1-year outcomes: a global perspective from the garfield-af registry 2015
Quantification of cell free DNA in red blood cell concentrates produced via buffy coat (B1) OR whole blood (B2) methods 2015
Reversal of dabigatran could be achieved by hemodialysis with or without other hemostatic agents 2015
Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF 2015
Risk-assessment model of recurrence within 3 months after a first episode of acute venous thromboembolism: Worcester venous thromboembolism study 2015
Rivaroxaban associates with factor Xa faster than apixaban: a potential explanation for their different effects on tests of coagulation 2015
Source data verification pilot: using central monitoring in an: observational critical care biomarker study 2015
Strategies and outcomes of periprocedural bridging therapy with low-molecular-weight-heparin in patients with mechanical heart valves 2015
Surveillance study of safety and efficacy of a VWF/FVIII concentrate in patients with von willebrand disease (WIL-20) - a planned interim analysis 2015
The effect of age on glycan microheterogeneity of human Alpha-2-macroglobulin 2015
The laboratory profile that predicts favorable outcome after Eculizumab therapy in patients with clinical features compatible with atypical hemolytic uremic syndrome 2015
Twice-daily dosing of ASA overcomes reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a randomized controlled trial 2015
Utilization of anti-inhibitors products and inhibitors status of severe hemophilia patients: 5 years national data from the Canadian hemophilia assessment and resource management system 2015
ZN(2+) accelerates clot formation, modifies clot structure, and promotes clot stability 2015
Investigating determinants of inhbitor development to factor VIII molecules in previously treated hemophilia A patients 2014
Major bleeding events with dabigatran versus warfarin in patients with acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II 2014
Reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for direct and indirect fXa inhibitors-a phase 2 randomized, double-blind, placebo-controlled trial 2014
Risk of inhibitor development in previously treated patients with positive inhibitor history or low titer of inhibitor at baseline: results of a survey of hemophilia experts 2014
Statin use reduces incidence of adverse events in patients with atrial fibrillation: analysis in ACTIVE-W & A and AVERROES studies 2014
Time course of recurrent venous thromboembolic and major bleeding events during anticoagulant therapy with apixaban or enoxaparin/warfarin: analysis of the amplify data using landmark method 2014
Vitamin K antagonists vs. heparin for the treatment of splanchnic vein thrombosis in the isth registry: results of 12-month follow-up and a propensity score analysis 2014
Risk of thromboembolism, recurrent bleeding and death after warfarin interruption for gastrointestinal bleeding 2013
The safety and efficacy of inferior vena cava filters: the experience of the Ottawa hospital 2013
Venous thromboembolism prophylaxis in elderly patients admitted to Italian internal medicine wards 2013
A comprehensive mutagenesis screen defines the substrate recognition landscape within VWF for ADAMTS13 2013
A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors 2013
A review of computed tomography pulmonary angiograms in three teaching hospitals: the rise of sub-segmental pulmonary emboli and their management 2013
A systematic review to evaluate thromboelastography for characterization of bleeding patients with advanced liver diseases 2013
Abnormal megakaryocyte development and platelet function in a mouse model of gray platelet syndrome 2013
Active site-mutated thrombin S195A but not active site-blocked thrombin counteracts the anticoagulant activity of dabigatran in plasma 2013
Adherence to anticoagulant treatment with dabigatran in a real-world setting 2013
An in vitro model studying the effects of rivaroxaban and dabigatran on clot formation in factor VIII-depleted plasma mimicking the plasma of hemophilia A patients 2013
Antithrombotic treatment of splanchnic vein thrombosis in the ISTH international registry: results of 6-month follow-up 2013
Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY) 2013
Applying phage display to screen a library of a1-protease inhibitor mutants for thrombin inhibitory activity 2013
Asian patients with splanchnic vein thrombosis: a sub-analysis from an international registry 2013
Aspirin for the prevention of recurrent venous thromboembolism (VTE): the INSPIRE collaboration 2013
Association between treatment regimen and quality of life assessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the HERO study 2013
Association of treatment regimen and location with bleed frequency, quality of life and comorbidities in adults and children with haemophilia from the HERO study 2013
Case fatality of antithrombotic therapy associated major bleeding or major trauma 2013
Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study 2013
Clots formed from y '-fibrinogen are more resistant to lysis than those formed from? A-fibrinogen because of delayed plasminogen activation by tissue plasminogen activator 2013
Covalently linking heparin to antithrombin diminishes the protective effect of fibrin on plasmin 2013
DNA and RNA promote kallikrein-mediated activation of fXII and are cofactors for fXI feedback activation by thrombin 2013
Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN Study 2013
Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations 2013
Development and accreditation of a standardized training program in thrombosis and vascular medicine - a Canadian initiative 2013
Different effects of antiplatelet vs. anticoagulant agents in mouse bleeding models 2013
Do bleed rates and haemophilia treatment centre/provider utilisation vary with physical activity risk in adults with haemophilia: An analysis from the HERO study 2013
Do inhibitors, treatment regimen and bleed frequency impact haemophilia treatment centre and provider utilisation: an analysis of adults with haemophilia in the HERO study 2013
Do inhibitors, treatment regimen and bleed frequency impact parent-directed haemophilia treatment centre and provider utilisation: An analysis of parents of children with haemophilia in the HERO study 2013
Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilisation in children with haemophilia: an analysis from the HERO study 2013
Effect of ethanol locks on occlusion of central venous catheters used for administration of total parenteral nutrition 2013
Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: first results of an individual patient data meta-analytic project 2013
Effects of three-factor and four-factor prothrombin complex concentrates on the pharmacodynamics of rivaroxaban 2013
Efficacy and safety of weight-adjusted extended duration tinzaparin for prevention of post-operative venous thromboembolism after bariatric surgery 2013
External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database 2013
Feasibility study of a randomized control trial to evaluate an internet-based self-management program for adolescents with hemophilia: preliminary results and observations 2013
Heterogeneity of bleeding classification among randomized studies in hemophilic patients 2013
High incidence of VTE despite electronic alerts for thromboprophylaxis in hospitalized cancer patients 2013
Histidine-rich glycoprotein binds to DNA, RNA and fXIIa with high affinity and attenuates contact-mediated coagulation in a mouse model of arterial thrombosis 2013
In vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma using thromboelastography 2013
Investigation of the contribution of von Willebrand factor (VWF) propeptide mutations to type 3 VWD using in vitro cellular studies and patient-derived blood outgrowth endothelial cells (BOEC) 2013
Lung cancer chemotherapy agents induce protein disulphide isomerase dependent tissue factor decryption resulting in increased procoagulant activity in vitro and in vivo 2013
Meta-analysis of Post Authorization Safety Studies: worldwide postmarking surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method rAHF-PFM 2013
Outcome of patients treated with plasma or prothrombin complex concentrates for warfarin related intracerebral hemorrhage 2013
Over-representation of thoracic outlet obstruction in patients with unprovoked upper extremity deep vein thrombosis 2013
Performance of fibrin monomer in the evaluation of patients with suspected pulmonary embolism 2013
Plasma fibronectin supports hemostasis, controls the diameter of fibrin fibers, and regulates thrombosis 2013
Potential relationships between negative impacts on employment or relationships and haemophilia treatment centre/provider utilisation: an analysis of adults with haemophilia from the HERO study 2013
Potential relationships between negative impacts on employment or relationships with haemophilia centre/provider utilisation: An analysis of parents of children with haemophilia from the HERO study 2013
Procoagulant red blood cells diminish the protective effect of prothrombinase on factor Xa inhibition by fondaparinux and low molecular weight heparin 2013
Protamine sulfate neutralization of anticoagulation by a potent antithrombin-heparin covalent complex 2013
Prothrombin activation intermediates bind thrombomodulin demonstrating sequential capacitation of exosite 1 2013
Prothrombin complex concentrate use for the emergency reversal of vitamin K antagonists 2013
Quality of life and well-being of haemophilia patients and parents in China: subgroup analysis of the HERO study 2013
Relationship of quality of life, pain and self-reported arthritis with activity, bleed rate and haemophilia treatment centre/provider utilisation: results from the HERO study 2013
Role of cell-free DNA in sepsis pathophysiology: novel studies in murine models of sepsis 2013
Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II 2013
Selective depletion of contact factors with antisense oligonucleotides attenuates catheter thrombosis in rabbits 2013
Serological investigation of 20 patients re-exposed to heparin with a previous history of heparin-induced thrombocytopenia (HIT) 2013
Subcutaneous injection of enoxaparin in neonates 2013
The clincal impact of anti-protamine/heparin antibodies in patients undergoing cardiac surgery 2013
The effect of rivaroxaban and dabigatran on the surface architecture of clots formed from plasma enriched with different levels of autologous platelets 2013
The prognostic significance of residual vein obstruction in patients with treated deep vein thrombosis: a patient-level meta-analysis 2013
The rate of reduction in D-dimer level for patients with venous thromboembolism responding to antithrombotic therapy 2013
The use of preoperative erythropoiesis-stimulating agents (ESAs) in patients who underwent knee or hip arthroplasty a meta-analysis of randomized clinical trials 2013
Utilization of FXIII concentrates by FXIII deficiency patients in Canadian hemophilia treatments centers: 10 years national data from the canadian hemophilia assessment and resource management system 2013
Venous thromboembolism: an annual European Union 27 cost-of-illness model for the burden of the disease 2013
Zinc inhibits fibrinolysis by attenuating plasminogen activation and fibrin degradation 2013
Kringle domains of plasmin are essential for efficient degradation of fibrin but not fibrinogen 2012
A prospective cohort study of bleeding symptoms among persons referred to hematologists who are diagnosed with or excluded of having bleeding disorders 2011
A randomized controlled trial comparing aspirin with dalteparin for the prevention of venous thromboembolism following total hip arthroplasty 2011
A thromboelastography study to evaluate the effect of thrombocytopenia on clot formation in the presence of unfractionated heparin 2011
Age-adjusted D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded 2011
Anticoagulant therapy in patients with thrombocytopenia: a systematic review of case series in medical literature 2011
Arterial thromboembolectomy and intraoperative anticoagulation in the setting of heparin-induced thrombocytopenia (HIT) 2011
Aspirin does not augment inhibition of human platelet responses to thrombin in the presence of P2Y(12) antagonism 2011
BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 and PDE 2011
Batroxobin and thrombin bind to distinct sites on fibrinogen and fibrin 2011
Bioequivalence of B-domain deleted and plasma derived FVIII concentrates 2011
Bleeding risks associated with inherited platelet disorders: results from a prospective cohort study 2011
Body mass index and thromboembolism in children with hematological malignancies 2011
Can the CHADS2 score predict postoperative stroke risk in patients with chronic atrial fibrillation who are having elective non-cardiac surgery? 2011
Catheter thrombosis with fondaparinux is prevented by thrombin inhibition in vitro and in rabbits 2011
Comparison of glycosylation profiles in various recombinant FVIII products and the effect of B-domain deletion 2011
Corn trypsin inhibitor coating attenuates the prothrombotic properties of coronary catheters in vitro and in rabbits 2011
Crystal structure and function of VKOR and its redox partner 2011
Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism 2011
Dabigatran vs. placebo for extended maintenance therapy of venous thromboembolism 2011
Development of a new immuno-activity assay for quantification of alpha-2-macroglobulin complexes 2011
Developmental effects on the glycosylation of anticoagulant protein C 2011
Diannexin, a homodimer of annexin A5 (A5), binds phosphatidylserine (PS) with high affinity and is a potent inhibitor of arterial thrombosis in mice 2011
Direct factor Xa and thrombin inhibitors: clinical trial update 2011
Does ABO blood group increase the rate of recurrent events after initial treatment for a first unprovoked venous thromboembolism (VTE) event? Reverse cohort subgroup analysis 2011
Dosing decisions in severe hemophilia a: can we aim lower? FVIII use in a cohort of Canadian patients in 2009 2011
Enhanced inhibition of platelet-prothrombinase by covalent antithrombin-heparin complex 2011
Extended follow-up of the multi-center prospective cohort that derived the 'men continue and HERDOO2' clinical decision rule identifying low risk unprovoked patients 2011
First analysis of 10-year trend in national factor concentrates usage in hemophilia: data from the Canadian hemophilia assessment and resource management system 2011
Fondaparinux treatment of acute heparin-induced thrombocytopenia (HIT) confirmed by a positive serotonin-release assay (SRA plus ) 2011
Four weeks vs. 12 weeks dosing interval for stable patients on warfarin: a randomized trial 2011
Genetic associations of pulmonary embolism among those with a deep vein thrombosis 2011
HERO - an international initiative exploring unmet psychosocial needs in haemophilia: results from a qualitative survey targeting 150 subjects in seven countries 2011
HERO, an international initiative exploring unmet psychosocial needs in haemophilia: characteristics of a quantitative survey targeting 1200 subjects in 12 countries 2011
HIT paradigms and paradoxes 2011
Heterogeneity of the clinical, laboratory and molecular markers of VWD type 3: results from the retrospective/prospective studies on 122/52 Italian patients 2011
High affinity binding of plasminogen to fibrin is not essential for efficient activation by tissue plasminogen activator 2011
Histidine-rich glycoprotein binds fibrinogen with high affinity and modulates thrombin binding to the gamma '-chain 2011
Impact of persistent antiphospholipid antibodies on symptomatic thromboembolism in children: a systematic review & meta-analysis [observational studies] 2011
Induction of endothelial von Willebrand's factor expression by precursor B lymphoblasts 2011
Inhibition of coagulation factors by covalent antithrombin-heparin in the presence of endothelium 2011
International registry on splanchnic vein thrombosis: description of the study population 2011
Investigation of in vitro microparticle clotting activity 2011
Measurement of platelet adenosine triphosphate release unexpectedly normalizes aggregation findings in some subjects, including persons with Quebec platelet disorder 2011
Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin conjugate 2011
No evidence of platelet activation in patients with atrial fibrillation who are treated with dabigatran: a substudy of the rely trial 2011
Onyx-3, a double-blind comparison of once- or twice-daily dosing with YM150 (30 or 60 mg daily) for preventing venous thromboembolism after elective hip arthroplasty 2011
Optimization of modified recombinant albumins that speed clot lysis by competing for crosslinking of antiplasmin 2011
Perioperative heparin bridging in patients receiving oral anticoagulation: meta-analysis of bleeding and thromboembolic rates 2011
Polyurethane immobilized with a covalent antithrombin-heparin complex for reducing thrombosis on blood contacting devices 2011
Probing the determinants of VWF substrate specificity for ADAMTS13 by M13 filamentous phage display 2011
Psychosocial aspects of living with haemophilia: the hero project and a narrative review of the published literature 2011
Randomized comparison of the DAWN AC computer program and a simple manual nomogram for quality of warfarin dosing 2011
Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells 2011
Reversal of dabigatran using recombinant activated factor vii and activated prothrombin complex concentrates in thromboelastography assay 2011
Role of plasma fibronectin in thrombosis and hemostasis: evidence for the fibrin-dependent and independent pathways 2011
Safe exclusion of deep vein thrombosis in primary and secondary care using the wells-rule; a large individual patient data meta-analysis 2011
Safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy 2011
Targeted gene sequencing of the protein C and EPCR genes in a large population of patients with unprovoked venous thromboembolism 2011
Thrombotic complications and thromboprophylaxis in single ventricle heart palliation in children 2011
Thrombus persistence and thrombotic-related complications after pediatric cardiac surgery 2011
Venous thromboembolism validation study of the improve risk assessment models in the medical patient (VTE-VALOURR) 2011
Vitamin K antagonist dosing methods and individual patient quality of INR control in the international active W anticoagulation study 2011
When assembled into their respective activation complexes, factors Xa, IXa, and VIIa are differentially protected from inhibition by the antithrombin/heparin complex 2011
XAMOS: A non-interventional study of rivaroxaban in the prophylaxis of venous thromboembolism after hip or knee surgery 2011
Zn2+ delays Glu-and Lys-plasminogen activation by tissue plasminogen activator and inhibits plasmin activity toward macromolecular substrates 2011
eNOS independent platelet inhibition by atorvastatin 2011
Clots formed from gamma '-fibrinogen are resistant to lysis because of impaired plasminogen activation by t-PA 2010
The role of activation peptide residues Lys42, Lys43, and Lys44 of TAFI in its activation by the thrombin-thrombomodulin complex 2010
A negative immunoturbidometric D-dimer as a stand-alone test excludes pulmonary embolism 2009
Alignment to prophylaxis guidelines and occurrence of venous thromboembolism after total hip and knee replacement 2009
Anticoagulant mechanisms of antithrombin-heparin studied by TEG 2009
Apixaban in patients with metastatic cancer: a randomized phase II feasibility study 2009
Audit of the clinical use of fresh-frozen plasma in umbria: study design and results 2009
Barriers to and potential solutions toward optimal prophylaxis against deep vein thrombosis for hospitalized medical patients: a survey of healthcare professionals 2009
Biomaterial surface modification with an antithrombin-heparin covalent complex for improved intravascular devices 2009
Bone mineral density in hemophilia patients: a meta-analysis 2009
Bruising in inherited disorders of primary hemostasis: results from a prospective study 2009
Burden of illness of venous thromboembolism after total hip and knee replacement in Canada 2009
Central nervous system (CNS) bleeding in patients with rare bleeding disorders (RBDS) 2009
Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism 2009
Comparison of recombinant and plasma-derived antithrombin biodistribution in vivo 2009
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the two coagulation disorders 2009
Computer assisted VKA monitoring with point of care device by general practitioners 2009
Covalent antithrombin-heparin and the protein C pathway 2009
Covalent linkage of heparin to antithrombin increases lung cell proliferation 2009
Covalently linking antithrombin to heparin enhances the inhibition of FXa in the prothrombinase complex 2009
D-dimer to predict thrombosis recurrence after unprovoked venous thromboembolism: effect of patient- and D-dimer-related factors on recurrence prediction 2009
D-dimer to predict thrombosis recurrence: comparison of aggregate data and individual patient data meta-analyses 2009
Decreased overall survival and increased risk of thrombosis in children with cancer and central venous line (CVL) dysfunction 2009
Development of factor V Leiden brochure 2009
Does heterogeneity in measured calibrated thrombin generation assay or FVIII activity (<1%) explain clinical heterogeneity in severe hemophilia A? 2009
Does patient sex and prior hormonal therapy predict risk for thrombosis recurrence after a first venous thromboembolism? 2009
Does the clinical presentation of venous thromboembolism predict the risk for and type of thrombosis recurrence? 2009
Dose-dependent effects of aspirin on platelet function 2009
Elevated levels of FVIIa-at following prednisone monotherapy in children with newly diagnosed acute lymphoblastic leukemia 2009
Equivalency of Tinzaparin and Enoxaparin children: a single centre report on efficacy and safety 2009
Evaluating the feasibility of less frequent INR testing during chronic anticoagulation therapy 2009
Experience of treating pediatric venous thromboembolism with low molecular weight heparin (LMWH) in an institute lack of anti-Xa monitoring support 2009
Factor VIII gene (F8) mutations as a predictor of outcome in immune tolerance induction (ITI) in hemophilia A patients with high-responding inhibitors 2009
Filter fracture and migration of a Gunther Tulip retrievable inferior vena cava filter 22 days after in a pediatric patient: a case report 2009
Hemorrhage in acute care setting is a risk factor for later venous thromboembolism in rehabilitation unit 2009
Incidence and predictors of serious bleeding following polypectomy in patients receiving and not receiving oral anticoagulation therapy 2009
Intracranial haemorrhage in haemophilia A and B: an italian retrospective survey 2009
JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism. a meta-analysis 2009
Long term (10 year) results from the canadian hemophilia primary prophylaxis study 2009
Long-term bleeding history as a tool for hemophilia management 2009
Loss of factor IX binding to collagen IV results in abnormal in vivo hemostasis and thrombosis 2009
Low-intensity adjusted-dose warfarin for the prevention of mechanical malfunction of doublelumen haemodialysis catheters: a randomized controlled trial 2009
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents 2009
Modelling thrombin generation in developmental hemostasis 2009
Multicentric evaluation of current dosing practice of recombinant fix in italy 2009
Natural history of mesenteric venous thrombosis in patients treated with oral anticoagulants 2009
Neonates: are they more prone to clotting or bleeding? 2009
Novel heparin cofactor II-dermatan sulfate covalent complex formation selects for dermatan sulfate with higher molecular weight 2009
Plasma derived (PD) and recombinant (R) factor VIII (FVIII) concentrates induce a different rate of inhibitor development in hemophilia A patients. a systematic review of the literature 2009
Production of VWF may mediate lymphoblast induced thrombin activation in children with newly diagnosed ALL 2009
Prospective assessment of clinical endpoints of VKA treatment in a primary care computer assisted management model 2009
Pulmonary function, C-reactive protein and cardiovascular risk in the moli-sani population 2009
Right atrial thrombosis in infants and children: literature review from 1981 to 2008 2009
Risk factors for recurrent thrombosis and anticoagulant-related bleeding in cancer patients 2009
Risk factors of bleeding severity in young boys with severe hemophilia a on tailored prophylaxis: long-term (10-year) results from the Canadian hemophilia primary prophylaxis study 2009
Selective detection of free plasmin using a chromogenic substrate bound to agarose beads 2009
Systematic literature review of iliac vein compression syndrome in pediatric patients 2009
The dynamics of platelet activation in vivo 2009
The effect of leptin on vascular calcification in apolipoprotein E - deficient mice 2009
The effect of low molecular weight heparin dalteparin in newly diagnosed ovarian cancer: a phase II randomized study 2009
Validation of a diagnostic approach to exclude recurrent venous thromboembolism 2009
Venous thromboembolism recurrence after a first episode of provoked venous thrombosis due to a transient risk factor. A systematic review of the literature 2009
Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes 2009
Combined antiplatelet and anticoagulant therapy: clinical benefits and risks 2007
Factor Xa or thrombin: Is thrombin a better target? 2007
New anticoagulants 2005
Unresolved issues in anticoagulant therapy 2003
High-dose intravenous immunoglobulin G and usual heparin anticoagulation for urgent cardiac surgery in a patient with severe autoimmune heparin-induced thrombocytopenia.. S1538-7836(24)00687-1. 2024
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years.. S1538-7836(24)00631-7. 2024
Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease.. S1538-7836(24)00579-8. 2024
"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19": reply.. 22:2672-2673. 2024
Perioperative management and outcomes in patients receiving low-dose rivaroxaban and/or aspirin: a subanalysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. 22:2227-2233. 2024
Rapid diagnosis of coagulopathies from vitamin K deficiency in a consecutive case cohort evaluated by comparative assessment of factor II by one stage assays with prothrombin time versus Ecarin reagents. 22:3059-3069. 2024
Small Molecules Targeting GRP78 Mitigate Anti- GRP78 Autoantibody-Mediated Tissue Factor Procoagulant Activity in Cultured Endothelial Cells. 22:3290-3304. 2024
The historical origins of modern international normalized ratio targets. 22:2184-2194. 2024
Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors. 22:2761-2766. 2024
Removing cross-cultural barriers to participation in the ISTH Congress. 22:1803-1805. 2024
Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 22:2889-2899. 2024
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. 22:1779-1797. 2024
A specific fluorescence resonance energy quenching–based biosensor for measuring thrombin activity in whole blood. 22:1627-1639. 2024
Hemostatic management of von Willebrand disease during childbirth with a plasma-derived von Willebrand factor/factor VIII concentrate. 22:2739-2744. 2024
Pediatric pulmonary thromboembolism: a 3-year Canadian Pediatric Surveillance Program study. 22:1366-1371. 2024
Lower-dose emicizumab prophylaxis: can less be more?. 22:922-925. 2024
Targeted ADAMTS-13 replacement therapy for thrombotic thrombocytopenic purpura. 22:896-904. 2024
Validation of the time to attain maximal clot amplitude after reaching maximal clot formation velocity parameter as a measure of fibrinolysis using rotational thromboelastometry and its application in the assessment of fibrinolytic resistance in septic patients: a prospective observational study: communication from the ISTH SSC Subcommittee on Fibrinolysis. 22:1223-1235. 2024
Periprocedural management of direct oral anticoagulants in patients with atrial fibrillation and active cancer. 22:727-737. 2024
Evaluation of laboratory testing parameters for vaccine-induced immune thrombotic thrombocytopenia and their implications for diagnosis. 22:304-306. 2024
Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model. 22:263-270. 2024
Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry. 21:3581-3588. 2023
Defining heparin resistance: communication from the ISTH SSC Subcommittee of Perioperative and Critical Care Thrombosis and Hemostasis. 21:3649-3657. 2023
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. 21:3450-3462. 2023
Risk stratification of acute pulmonary embolism. 21:3016-3023. 2023
Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials. 21:3067-3071. 2023
Accuracy of physicians’ intuitive risk estimation in the diagnostic management of pulmonary embolism: an individual patient data meta-analysis. 21:2873-2883. 2023
Antibodies against platelet factor 4 and the risk of cerebral venous sinus thrombosis in patients with vaccine-induced immune thrombotic thrombocytopenia. 21:2833-2843. 2023
Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. 21:2963-2976. 2023
Use of patient-reported outcome measures in patients with venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. 21:2953-2962. 2023
Hemophilia gene therapy: first, do no harm. 21:2354-2361. 2023
Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT. 21:2268-2276. 2023
Metalloprotease domain latency protects ADAMTS13 against broad-spectrum inhibitors of metalloproteases while maintaining activity toward VWF. 21:1789-1801. 2023
News at XI: moving beyond factor Xa inhibitors. 21:1692-1702. 2023
Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. 21:1592-1600. 2023
Decision-analysis modeling of effectiveness and cost-effectiveness of pharmacologic thromboprophylaxis for surgical inpatients using variable risk assessment models or other strategies. 21:1580-1591. 2023
Multidisciplinary care of the pregnant patient with or at risk for venous thromboembolism: a recommended toolkit from the Foundation for Women and Girls with Blood Disorders Thrombosis Subcommittee. 21:1432-1440. 2023
Impact of SERPINC1 mutation on thrombotic phenotype in children with congenital antithrombin deficiency—first analysis of the International Society on Thrombosis and Haemostasis pediatric antithrombin deficiency database and biorepository. 21:1248-1257. 2023
Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation. 21:1381-1384. 2023
Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. 21:1043-1054. 2023
Thrombotic and bleeding outcomes following the perioperative interruption of anticoagulation among patients with nonvalvular atrial fibrillation and active cancer. 21:933-943. 2023
The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism. 21:553-558. 2023
Allosteric modulation of exosite 1 attenuates polyphosphate-catalyzed activation of factor XI by thrombin. 21:83-93. 2023
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro. 21:76-82. 2023
“Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia”: reply. 21:185-185. 2023
Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure. 20:2953-2963. 2022
Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia. 20:2988-2997. 2022
Mechanisms of ADAMTS13 regulation. 20:2722-2732. 2022
Peri‐procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH. 20:3026-3038. 2022
Challenges facing early career women in thrombosis and hemostasis—meeting the needs of the next generation. 20:2453-2455. 2022
“ISTH guidelines for antithrombotic treatment in COVID‐19”: Reply. 20:2710-2711. 2022
Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH. 20:2226-2236. 2022
ISTH guidelines for antithrombotic treatment in COVID‐19. 20:2214-2225. 2022
A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates. 20:2012-2021. 2022
Direct oral anticoagulants after bariatric surgery—What is the evidence?. 20:1988-2000. 2022
Frequency and utility of bone marrow examination in relapsed/refractory immune thrombocytopenia. 20:2119-2126. 2022
Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. 20:1910-1919. 2022
ISTH Biennial Impact Report: Looking back and looking forward. 20:1515-1517. 2022
von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient‐derived endothelial colony‐forming cells. 20:1599-1609. 2022
Investigations of the effectiveness of heparin variants as inhibitors of histones. 20:1485-1495. 2022
Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature. 20:1364-1375. 2022
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. 20:1193-1205. 2022
Identification of the histidine‐rich glycoprotein domains responsible for contact pathway inhibition. 20:821-832. 2022
An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta‐analysis. 20:409-421. 2022
Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. 20:532-535. 2022
Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE. 20:366-374. 2022
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) ‐ update on diagnosis and management considering different resources: Response to Comment from Yamada et al. 20:542-543. 2022
Multicentre evaluation of 5B9, a monoclonal anti‐PF4/heparin IgG mimicking human HIT antibodies, as an internal quality control in HIT functional assays: Communication from the ISTH SSC Subcommittee on Platelet Immunology. 20:252-259. 2022
Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources. 20:149-156. 2022
Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD‐VTE. 19:3031-3043. 2021
Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. 19:3008-3017. 2021
Use of novel antithrombotic agents for COVID‐19: Systematic summary of ongoing randomized controlled trials. 19:3080-3089. 2021
Direct oral anticoagulant dose selection: Challenging cases. 19:2680-2686. 2021
Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis. 19:2801-2813. 2021
Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. 19:2726-2737. 2021
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. 19:2772-2780. 2021
Detection of right ventricular dysfunction in acute pulmonary embolism by computed tomography or echocardiography: A systematic review and meta‐analysis. 19:2504-2513. 2021
Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients. 19:2495-2503. 2021
Recurrent bleeding and thrombotic events after resumption of oral anticoagulants following gastrointestinal bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. 19:2618-2628. 2021
Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. 19:2348-2354. 2021
Reduced‐dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: A systematic review and meta‐analysis—Response to Commentary. 19:2359-2360. 2021
Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD‐AF Registry. 19:2322-2334. 2021
Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. 19:2082-2088. 2021
Terminal half‐life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. 19:1896-1906. 2021
The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. 19:2094-2095. 2021
A simplified decision rule to rule out deep vein thrombosis using clinical assessment and D‐dimer. 19:1752-1758. 2021
International Society on Thrombosis and Haemostasis: Present and future. 19:1599-1601. 2021
Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study. 19:1546-1557. 2021
Long‐term risk of recurrent venous thromboembolism after a first contraceptive‐related event: Data from REVERSE cohort study. 19:1526-1532. 2021
Recommendations for the clinical and laboratory diagnosis of VITT against COVID‐19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. 19:1585-1588. 2021
Platelet‐activating immune complexes identified in critically ill COVID‐19 patients suspected of heparin‐induced thrombocytopenia. 19:1342-1347. 2021
Severe thrombophilia in a factor V‐deficient patient homozygous for the Ala2086Asp mutation (FV Besançon). 19:1186-1199. 2021
The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. 19:1364-1371. 2021
A comparative study of platelet factor 4‐enhanced platelet activation assays for the diagnosis of heparin‐induced thrombocytopenia. 19:1096-1102. 2021
Clinical history of cancer‐associated splanchnic vein thrombosis. 19:983-991. 2021
Definition of haemostatic effectiveness in interventions used to treat major bleeding: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation. 19:1112-1115. 2021
International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis. 19:1123-1129. 2021
Novel bleeding risk score for patients with atrial fibrillation on oral anticoagulants, including direct oral anticoagulants. 19:931-940. 2021
Communication from the ISTH SSC Subcommittee on Women's Health Issues in Thrombosis and Haemostasis: A Survey on Anticoagulation for Mechanical Heart Valves in Pregnancy. 19:859-864. 2021
Incidence and predictors of splanchnic vein thrombosis and mortality following hepatobiliary and pancreatic surgery. 19:797-804. 2021
Multimerin 1 supports platelet function in vivo and binds to specific GPAGPOGPX motifs in fibrillar collagens that enhance platelet adhesion. 19:547-561. 2021
Dr. M. Patricia Massicotte Obituary. 19:313-314. 2021
Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. 19:30-40. 2021
International survey on Helicobacter pylori testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. 19:287-296. 2021
Management of antithrombotic therapy after gastrointestinal bleeding: A mixed methods study of health‐care providers. 19:153-160. 2021
New anticoagulants: Moving beyond the direct oral anticoagulants. 19:20-29. 2021
Professor Marian A. Packham, CM, PhD, DSc, FRSC (1927–2020). 19:311-312. 2021
Pulmonary embolism prevalence among emergency department cohorts: A systematic review and meta‐analysis by country of study. 19:173-185. 2021
Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH. 18:3174-3183. 2020
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. 18:3074-3077. 2020
Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. 18:2503-2512. 2020
ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. 18:2486-2495. 2020
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. 18:2496-2502. 2020
Identification of hemostatic markers that define the pre‐DIC state: A multi‐center observational study. 18:2524-2531. 2020
Obituary for Dr. Clive Kearon. 18:2783-2784. 2020
Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets. 18:2364-2376. 2020
Diagnosing deep vein thrombosis in cancer patients with suspected symptoms: An individual participant data meta‐analysis. 18:2245-2252. 2020
Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta‐analysis. 18:2308-2317. 2020
ISTH DIC subcommittee communication on anticoagulation in COVID‐19. 18:2138-2144. 2020
Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta‐analysis. 18:2274-2286. 2020
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials. 18:2287-2295. 2020
The need for accurate D‐dimer reporting in COVID‐19: Communication from the ISTH SSC on fibrinolysis. 18:2408-2411. 2020
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. 18:2126-2137. 2020
Maximum 24‐hour platelet count fall: Metric for improving the diagnosis of heparin‐induced thrombocytopenia among patients with intermediate probability 4Ts scores. 18:2018-2024. 2020
Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19. 18:1859-1865. 2020
Anticoagulant therapy for splanchnic vein thrombosis. 18:1562-1568. 2020
Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta‐analysis. 18:1661-1671. 2020
Management of major bleeds in patients with immune thrombocytopenia. 18:1783-1790. 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation. 18:1672-1685. 2020
Combination of two complementary automated rapid assays for diagnosis of heparin‐induced thrombocytopenia (HIT). 18:1435-1446. 2020
Definition of pulmonary embolism‐related death and classification of the cause of death in venous thromboembolism studies: Communication from the SSC of the ISTH. 18:1495-1500. 2020
Development of a standardized definition of pulmonary embolism‐related death: A cross‐sectional survey of international thrombosis experts. 18:1415-1420. 2020
RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis‐induced coagulopathy than fibrin‐related markers: Response to the Letter‐to‐the‐Editor by Dr Wada. 18:1507-1509. 2020
Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio > 10. 18:1133-1140. 2020
Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m). 18:905-915. 2020
Clinical pre‐test probability adjusted versus age‐adjusted D‐dimer interpretation strategy for DVT diagnosis: A diagnostic individual patient data meta‐analysis. 18:669-675. 2020
Defining trauma‐induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. 18:740-747. 2020
Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. 18:732-739. 2020
Ability of a single negative ultrasound to rule out deep vein thrombosis in pregnant women: A systematic review and meta‐analysis. 18:373-380. 2020
Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis. 18:422-438. 2020
Prevention of venous thromboembolism in medical cancer patients: Guidance or guideline?. 18:520-521. 2020
Reply to Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. 18:519-520. 2020
Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis. 17:2081-2088. 2019
Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation. 17:1989-1994. 2019
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post‐hoc analysis of the Hokusai‐VTE Cancer study. 17:1866-1874. 2019
Ischemic limb necrosis in septic shock: What is the role of high‐dose vasopressor therapy?. 17:1973-1978. 2019
Purification of silica‐free DNA and characterization of its role in coagulation. 17:1860-1865. 2019
Scientific and Standardization Committee Communication: Guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: Recommendations for standardized reporting of procedural/surgical bleed risk and patient‐specific thromboembolic risk. 17:1966-1972. 2019
The risk of major bleeding in patients with suspected heparin‐induced thrombocytopenia. 17:1956-1965. 2019
Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients. 17:1694-1706. 2019
Toll-like receptors 2 and 7 mediate coagulation activation and coagulopathy in murine sepsis.. 17:1683-1693. 2019
Corrigendum. 17:1578-1578. 2019
Emicizumab and thrombosis: The story so far. 17:1269-1272. 2019
Proposal of a two‐step process for the diagnosis of sepsis‐induced disseminated intravascular coagulation. 17:1265-1268. 2019
An assay to measure levels of factor Xa inhibitors in blood and plasma. 17:1153-1159. 2019
Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. 17:1085-1096. 2019
Long‐term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d‐dimer results; A cohort study. 17:1144-1152. 2019
Periprocedural interruption of anticoagulation in patients with cancer‐associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. 17:1171-1178. 2019
High‐dose intravenous immunoglobulin to treat spontaneous heparin‐induced thrombocytopenia syndrome. 17:841-844. 2019
The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta‐analysis of a diagnostic test. 17:787-794. 2019
An international external quality assessment for laboratory diagnosis of heparin‐induced thrombocytopenia. 17:525-531. 2019
Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin‐induced thrombocytopenia. 17:389-399. 2019
Differential diagnoses for sepsis‐induced disseminated intravascular coagulation: communication from the SSC of the ISTH. 17:415-419. 2019
Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. 16:2526-2529. 2018
Heparin‐induced thrombocytopenia‐associated thrombosis: from arterial to venous to venous limb gangrene. 16:2128-2132. 2018
Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke. 16:1932-1940. 2018
Weight‐adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. 16:2008-2015. 2018
Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia. 16:1402-1412. 2018
Pharmacokinetics and the transition to extended half‐life factor concentrates: communication from the SSC of the ISTH. 16:1437-1441. 2018
Questioning the use of an age‐adjusted D‐dimer threshold to exclude venous thromboembolism: reply. 16:1448-1450. 2018
Reduced‐dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta‐analysis. 16:1288-1295. 2018
Addressing the burden of hospital‐related venous thromboembolism: the role of extended anticoagulant prophylaxis. 16:413-417. 2018
Erratum. 16:609-609. 2018
Age‐adjusted D‐dimer to rule out deep vein thrombosis: findings from the PALLADIO algorithm. 16:271-278. 2018
Development of a clinical prediction model for the postthrombotic syndrome in a prospective cohort of patients with proximal deep vein thrombosis. 16:262-270. 2018
Recommendations for future research in relation to pediatric pulmonary embolism: communication from the SSC of the ISTH. 16:405-408. 2018
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. 16:1656-1664. 2018
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. 16:54-64. 2018
The identification of at‐risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. 16:175-180. 2018
Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. 15:2377-2387. 2017
Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. 15:2461-2465. 2017
Autoimmune heparin‐induced thrombocytopenia. 15:2099-2114. 2017
Recommendations for standardized risk factor definitions in pediatric hospital‐acquired venous thromboembolism to inform future prevention trials: communication from the SSC of the ISTH. 15:2274-2278. 2017
Association between remote major venous thromboembolism risk factors and the risk of recurrence after a first unprovoked episode. 15:1977-1980. 2017
Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. 15:1913-1922. 2017
Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. 15:1878-1881. 2017
Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta‐analysis of randomized controlled trials. 15:1547-1558. 2017
Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin‐induced thrombocytopenia. 15:1640-1645. 2017
Diagnostic accuracy of IgG‐specific versus polyspecific enzyme‐linked immunoassays in heparin‐induced thrombocytopenia: a systematic review and meta‐analysis. 15:1203-1212. 2017
Once versus twice daily aspirin after coronary bypass surgery: a randomized trial. 15:889-896. 2017
Questioning the use of an age‐adjusted D‐dimer threshold to exclude venous thromboembolism: analysis of individual patient data from two diagnostic studies: reply. 14:2555-2556. 2016
To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. 14:2556-2559. 2016
Histones link inflammation and thrombosis through the induction of Weibel–Palade body exocytosis. 14:2274-2286. 2016
Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH. 14:2304-2307. 2016
Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is ‘shock liver’ the unrecognized provocateur of ischemic limb necrosis: reply. 14:2317-2319. 2016
Questioning the use of an age‐adjusted D‐dimer threshold to exclude venous thromboembolism: analysis of individual patient data from two diagnostic studies. 14:1953-1959. 2016
Protamine (heparin)‐induced thrombocytopenia: a review of the serological and clinical features associated with anti‐protamine/heparin antibodies. 14:1685-1695. 2016
Thrombolysis by chemically modified coagulation factor Xa. 14:1844-1854. 2016
Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. 14:1668-1672. 2016
International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis: comment. 14:1316-1317. 2016
Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study. 14:1206-1210. 2016
Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 14:875-885. 2016
Rapid quantitative D‐dimer to exclude pulmonary embolism: a prospective cohort management study. 14:504-509. 2016
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. 14:623-627. 2016
Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells. 14:366-374. 2016
Shock, acute disseminated intravascular coagulation, and microvascular thrombosis: is ‘shock liver’ the unrecognized provocateur of ischemic limb necrosis?. 14:231-235. 2016
Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. 14:211-214. 2016
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. 14:143-152. 2016
Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. 14:89-97. 2016
Evaluation of and recommendation for the nomenclature of the CPB2 gene product (also known as TAFI and proCPU): communication from the SSC of the ISTH. 13:2277-2278. 2015
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. 13:2187-2191. 2015
Corrigendum. 13:2134-2134. 2015
Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH. 13:2119-2126. 2015
Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials. 13:2012-2020. 2015
Distinguishing between anti–platelet factor 4/heparin antibodies that can and cannot cause heparin‐induced thrombocytopenia. 13:1900-1907. 2015
Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review. 13:1790-1798. 2015
The prediction of postoperative stroke or death in patients with preoperative atrial fibrillation undergoing non‐cardiac surgery: a VISION sub‐study. 13:1768-1775. 2015
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings. 13:1597-1605. 2015
Global public awareness of venous thromboembolism. 13:1365-1371. 2015
Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: reply. 13:1522-1523. 2015
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis: comment. 13:1162-1164. 2015
Extracellular DNA and histones: double‐edged swords in immunothrombosis. 13:S82-S91. 2015
Medical device‐induced thrombosis: what causes it and how can we prevent it?. 13:S72-S81. 2015
Postoperative atrial fibrillation in non‐cardiac and cardiac surgery: an overview. 13:S304-S312. 2015
Real-world variability in dabigatran levels in patients with atrial fibrillation: reply. 13:1168-1169. 2015
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. 13:1010-1018. 2015
Role of aspirin for prevention and treatment of perioperative cardiovascular events. 13:S297-S303. 2015
Treatment of acute ischemic stroke: from fibrinolysis to neurointervention. 13:S290-S296. 2015
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. 13:1028-1035. 2015
Use of genetic data to guide therapy in arterial disease. 13:S281-S289. 2015
Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial. 13:699-707. 2015
Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. 13:775-781. 2015
Recommendations for standardization of laboratory testing for drug‐induced immune thrombocytopenia: communication from the SSC of the ISTH. 13:676-678. 2015
Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. 13:347-352. 2015
Corrigendum. 13:489-489. 2015
Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post‐thrombotic syndrome. 13:398-408. 2015
Multiple daily doses of acetyl‐salicylic acid (ASA) overcome reduced platelet response to once‐daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial. 13:448-456. 2015
Real‐world variability in dabigatran levels in patients with atrial fibrillation. 13:353-359. 2015
Recommendations for the assessment of non‐extremity venous thromboembolism outcomes: communication from the SSC of the ISTH. 13:477-480. 2015
Recommendations for the development of new anticoagulant drugs for pediatric use: communication from the SSC of the ISTH. 13:481-484. 2015
Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. 13:457-464. 2015
Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. 13:314-322. 2015
Sub‐segmental pulmonary embolism in three academic teaching hospitals: a review of management and outcomes. 13:214-218. 2015
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents. 12:1810-1815. 2014
Corrigendum. 12:1948-1948. 2014
Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. 12:1816-1821. 2014
Guidance, guidelines, and communications. 12:1744-1745. 2014
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. 12:1626-1635. 2014
Comparing mortality in patients with atrial fibrillation who are receiving a direct‐acting oral anticoagulant or warfarin: a meta‐analysis of randomized trials. 12:1419-1424. 2014
Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. 12:1428-1436. 2014
Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. 12:1562-1569. 2014
Monitoring the anticoagulant effect after a massive rivaroxaban overdose. 12:1570-1571. 2014
Loading dose vs. maintenance dose of warfarin for reinitiation after invasive procedures: a randomized trial. 12:1254-1259. 2014
γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. 12:1110-1115. 2014
Dabigatran versus warfarin in patients with mechanical heart valves: reply. 12:426-426. 2014
Extended‐duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: a meta‐analysis of the randomized controlled trials. 12:107-109. 2014
Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen–deuterium exchange mass spectrometry. 11:2128-2136. 2013
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression. 11:1655-1662. 2013
Recommendations for prophylaxis of pregnancy‐related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines: a rebuttal. 11:1782-1784. 2013
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. 11:1443-1448. 2013
Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 11:1593-1596. 2013
Adherence to anticoagulant treatment with dabigatran in a real‐world setting. 11:1295-1299. 2013
FcγRIIa proteolysis as a diagnostic biomarker for heparin-induced thrombocytopenia. 11:1146-1153. 2013
Insights into thrombin activatable fibrinolysis inhibitor function and regulation. 11:306-315. 2013
Optimal treatment duration of venous thrombosis. 11:151-160. 2013
Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. 11:1183-1189. 2013
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. 11:778-782. 2013
Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. 11:460-466. 2013
Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. 11:474-480. 2013
Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. 11:491-502. 2013
The accuracy of the International Normalized Ratio and the American College of Chest Physicians recommendations on the use of vitamin K to reverse over-anticoagulation: a rebuttal. 11:566-567. 2013
Tossing a coin or using common sense. 11:432-434. 2013
Anti‐PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. 11:253-260. 2013
Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. 11:245-252. 2013
A guide to GRADE guidelines for the readers of JTH. 11:1603-1608. 2013
A response to–There’s madness in their methods. 11:785-786. 2013
A systematic evaluation of laboratory testing for drug‐induced immune thrombocytopenia. 11:169-176. 2013
Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. 11:177-179. 2013
Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm?. 10:2621-2624. 2012
Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. 10:2494-2502. 2012
Risk of post‐thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. 10:2039-2044. 2012
Standardization of post‐thrombotic syndrome definition and outcome assessment following upper venous system thrombosis in pediatric practice. 10:2182-2185. 2012
Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. 10:1830-1840. 2012
A prospective study measuring the development of antibodies against platelet factor 4–heparin in healthy males after exposure to heparins. 10:1446-1449. 2012
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. 10:1433-1436. 2012
Comparison of the Villalta post‐thrombotic syndrome score in the ipsilateral vs. contralateral leg after a first unprovoked deep vein thrombosis. 10:1036-1042. 2012
Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet‐mediated events during thrombus formation. 10:1109-1119. 2012
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). 10:1019-1025. 2012
When is it safe to stop for safety?. 10:1188-1190. 2012
A Protease TAMER: a nucleic acid‐based anticoagulant. 10:867-869. 2012
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. 10:807-814. 2012
Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation. 10:966-968. 2012
Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE‐HIP1, SAVE‐HIP2 and SAVE‐KNEE. 10:822-832. 2012
Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta‐analysis. 10:512-520. 2012
Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH. 10:698-702. 2012
Failure to correct International Normalized Ratio and mortality among patients with warfarin‐related major bleeding: an analysis of electronic health records. 10:596-605. 2012
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 10:692-694. 2012
Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia. 10:695-697. 2012
Reversal of the anti‐platelet effects of aspirin and clopidogrel. 10:521-528. 2012
Definition of post‐thrombotic syndrome following lower extremity deep venous thrombosis and standardization of outcome measurement in pediatric clinical investigations. 10:477-480. 2012
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal. 10:502-504. 2012
Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti‐factor Xa levels. 10:368-374. 2012
Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high‐risk neurosurgical patients. 10:229-235. 2012
Intraoperative anticoagulation and limb amputations in patients with immune heparin‐induced thrombocytopenia who require vascular surgery. 10:148-150. 2012
Recommendations for developing uniform laboratory monitoring of heparinoid anticoagulants in children. 10:145-147. 2012
Fondaparinux treatment of acute heparin‐induced thrombocytopenia confirmed by the serotonin‐release assay: a 30‐month, 16‐patient case series. 9:2389-2396. 2011
Laboratory testing for heparin‐induced thrombocytopenia: a conceptual framework and implications for diagnosis. 9:2498-2500. 2011
Retention of thrombin inhibitory activity by recombinant serpins expressed as integral membrane proteins tethered to the surface of mammalian cells. 9:2424-2435. 2011
Breast cancer chemotherapy induces the release of cell‐free DNA, a novel procoagulant stimulus. 9:2313-2321. 2011
Concentrate‐related inhibitor risk: is a difference always real?. 9:2176-2179. 2011
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial. 9:2168-2175. 2011
HIT paradigms and paradoxes. 9:105-117. 2011
Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. 9:1126-1132. 2011
The association between platelet activation and FcγRIIa proteolysis. 9:885-887. 2011
The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal‐based and cell‐based models. 9:767-775. 2011
Activated protein C modulates inflammation, apoptosis and tissue factor procoagulant activity by regulating endoplasmic reticulum calcium depletion in blood monocytes. 9:582-592. 2011
Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice. 8:2743-2750. 2010
The HIT Expert Probability (HEP) Score: a novel pre‐test probability model for heparin‐induced thrombocytopenia based on broad expert opinion. 8:2642-2650. 2010
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis. 8:2436-2442. 2010
Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. 8:2369-2376. 2010
Anticoagulant response after dalteparin overdose. 8:2321-2323. 2010
Direct and indirect costs of management of long‐term warfarin therapy in Canada. 8:2192-2200. 2010
Intracranial and fatal bleeding according to indication for long‐term oral anticoagulant therapy. 8:2201-2207. 2010
Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. 8:2313-2315. 2010
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. 8:1966-1975. 2010
Heparin‐induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. 8:2025-2031. 2010
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. 8:2063-2065. 2010
PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. 8:1959-1965. 2010
Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism. 8:1926-1932. 2010
Surveillance duplex scanning to prevent venous thromboembolism: does it make a difference in rehabilitation unit patients?. 8:1872-1874. 2010
Non‐necrotizing heparin‐induced skin lesions and the 4T’s score. 8:1483-1485. 2010
Definition of major bleeding in surgery: an anesthesiologist’s point of view: reply to a rebuttal. 8:1443-1444. 2010
Does dabigatran improve stroke‐prevention in atrial fibrillation? Reply to a rebuttal. 8:1438-1439. 2010
Inferior vena caval filter insertion prior to bariatric surgery: a systematic review of the literature. 8:1266-1270. 2010
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review. 8:1256-1265. 2010
D-dimer testing in pregnant patients: towards determining the next ‘level’ in the diagnosis of deep vein thrombosis. 8:1004-1011. 2010
Risk of stroke after surgery in patients with and without chronic atrial fibrillation. 8:884-890. 2010
The risk of cancer in patients with venous thromboembolism does not exceed that expected in the general population after the first 6 months. 8:1126-1127. 2010
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. 8:641-650. 2010
How can we reduce disagreement among guidelines for venous thromboembolism prevention?. 8:675-677. 2010
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX‐2). 8:714-721. 2010
Twelve‐month outcomes and predictors of very stable INR control in prevalent warfarin users. 8:744-749. 2010
Anti‐PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non‐drug risk factors and evidence for a stoichiometry‐based model of immunization. 8:504-512. 2010
Vitamin K to reverse the anticoagulant effect of vitamin K antagonists: can you teach an old dog new tricks?. 8:496-498. 2010
Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)‐5 trial. 8:243-249. 2010
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. 8:202-204. 2010
Early‐onset and persisting thrombocytopenia in post‐cardiac surgery patients is rarely due to heparin‐induced thrombocytopenia, even when antibody tests are positive. 8:30-36. 2010
Effect of a simple two‐step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. 8:101-106. 2010
Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis. 8:148-156. 2010
The use of well‐characterized sera for the assessment of new diagnostic enzyme‐immunoassays for the diagnosis of heparin‐induced thrombocytopenia. 8:216-218. 2010
Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. 7:1982-1989. 2009
Perioperative management of antithrombotic therapy: lifting the fog. 7:1979-1981. 2009
Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV. 7:1843-1851. 2009
Clinical probability score and D‐dimer estimation lack utility in the diagnosis of childhood pulmonary embolism. 7:1633-1638. 2009
The absence of `minor' risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios. 7:1619-1628. 2009
Effect of anti‐platelet factor‐4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. 7:1457-1464. 2009
The cost‐effectiveness of computer‐assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study. 7:1482-1490. 2009
The paradox of heparin‐induced thrombocytopenia. 7:1472-1473. 2009
Getting intimate with the venous thrombus. 7:1266-1267. 2009
Immunoassays are not created equal. 7:1256-1259. 2009
Antiphospholipid and anti‐PF4 antibodies: an association affecting anti‐PF4/heparin assay analysis. 7:1067-1069. 2009
Preface. 7:1-1. 2009
Recommendations on biosimilar low‐molecular‐weight heparins. 7:1222-1225. 2009
Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. 7:1029-1029. 2009
Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. 7:780-786. 2009
Validation of a diagnostic approach to exclude recurrent venous thromboembolism. 7:752-759. 2009
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose-ranging study. 7:566-572. 2009
Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. 7:676-684. 2009
Platelet adhesion to multimerin 1 in vitro: influences of platelet membrane receptors, von Willebrand factor and shear. 7:685-692. 2009
The long-term risk of cancer in patients with a first episode of venous thromboembolism. 7:546-551. 2009
Heparin‐induced thrombocytopenia (HIT) during postoperative warfarin thromboprophylaxis: a second example of postorthopedic surgery ‘spontaneous’ HIT. 7:499-501. 2009
Current perspective of venous thrombosis in the upper extremity: a rebuttal. 7:237-238. 2009
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. 7:58-64. 2009
the interpretation of light transmittance platelet aggregation is inconsistent-results from an international challenge: Oc-mo-134. 7:159-159. 2009
Heparin‐induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes. 6:2160-2167. 2008
Thrombophilic polymorphism – a short‐term or long‐term risk for recurrence?. 6:2225-2226. 2008
Differences in clinical presentation of deep vein thrombosis in men and women. 6:1713-1719. 2008
Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. 6:1615-1621. 2008
Activated thrombin‐activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation. 6:1600-1602. 2008
An algorithm for resolving ‘indeterminate’ test results in the platelet serotonin release assay for investigation of heparin‐induced thrombocytopenia. 6:1595-1597. 2008
Fatal heparin‐induced thrombocytopenia (HIT) during warfarin thromboprophylaxis following orthopedic surgery: another example of ‘spontaneous’ HIT?. 6:1598-1600. 2008
The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. 6:1507-1513. 2008
More on: vitamin K antagonists and cancer. 6:1442-1443. 2008
Quantitative interpretation of optical density measurements using PF4‐dependent enzyme‐immunoassays. 6:1304-1312. 2008
Can heparin‐induced thrombocytopenia be associated with fondaparinux use? Reply to a rebuttal. 6:1243-1246. 2008
D‐dimer testing is useful to exclude deep vein thrombosis in elderly outpatients. 6:1072-1076. 2008
Validation of a composite score for clinical severity of hemophilia. 6:1113-1121. 2008
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. 6:935-943. 2008
A case of non‐resolving hemophilia B Leyden in a 42‐year‐old male (F9 promoter + 13 A>G). 6:885-886. 2008
Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. 6:405-414. 2008
Heparin-induced thrombocytopenia in patients requiring prolonged intensive care unit treatment after cardiopulmonary bypass. 6:428-435. 2008
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. 6:457-463. 2008
An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. 6:395-397. 2008
An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. 6:395-397. 2008
Elevated tissue factor procoagulant activity in CD133‐positive cancer cells. 5:2550-2552. 2007
Bridging therapy in patients on long‐term oral anticoagulants who require surgery: the Prospective Peri‐operative Enoxaparin Cohort Trial (PROSPECT). 5:2211-2218. 2007
Performance characteristics of a rapid assay for anti‐PF4/heparin antibodies: the particle immunofiltration assay. 5:2308-2310. 2007
The management of anticoagulated patients requiring dental extraction: a cross‐sectional survey of oral and maxillofacial surgeons and hematologists. 5:2157-2159. 2007
Thrombophilia and location of venous thromboembolism. 5:2151-2152. 2007
Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study. 5:1914-1922. 2007
Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double‐blind comparison. 5:1854-1861. 2007
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. 5:1660-1665. 2007
Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. 5:1666-1673. 2007
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. 5:1438-1443. 2007
CLINICALLY - IMPORTANT VENOUS THROMBOEMBOLISM (CIVTE) FOLLOWING ISOLATED LEG FRACTURES DISTAL TO THE KNEE: EPIDEMIOLOGY AND PREVENTION: THE D-KAF (DALTEPARIN IN KNEE TO ANKLE FRACTURE) TRIAL. 5:o-t-051-o-t-051. 2007
DALTEPARIN THROMBOPROPHYLAXIS IN CRITICALLY ILL PATIENTS WITH SEVERE RENAL INSUFFICIENCY: THE DIRECT STUDY. 5:p-s-680-p-s-680. 2007
EFFECT OF AGE ON THE RELATIONSHIP BETWEEN RATE OF HEPARIN-CATALYZED INHIBITION OF COAGULATION FACTORS BY ANTITHROMBIN AND IN VIVO PLASMA CONCENTRATION. 5:p-w-052-p-w-052. 2007
EVALUATION OF THE ACCURACY OF A 99MTC-LABELLED MONOCLONAL ANTIBODY SPECIFIC FOR D-DIMER IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS (DVT). 5:p-s-606-p-s-606. 2007
EXTRA- AND INTRA-REACTIVE CENTRE LOOP ALTERATIONS TO ALPHA-1-PROTEINASE INHIBITOR ENHANCE ITS SPECIFIC INHIBITION OF THROMBIN. 5:o-t-087-o-t-087. 2007
MANAGEMENT OF VENOUS AND ARTERIAL THROMBOSIS IN CHILDREN. 5:sym-w-060-sym-w-060. 2007
NASCOLA SURVEY OF HIT TESTING IN NORTH AMERICA. 5:p-m-336-p-m-336. 2007
NEONATAL RENAL VEIN THROMBOSIS - 15 YEARS OF LITERATURE. 5:p-s-591-p-s-591. 2007
RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA (NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS. 5:p-t-162-p-t-162. 2007
Testing for heparin‐induced thrombocytopenia: are we there yet?. 5:1371-1372. 2007
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. 5:1431-1437. 2007
Linkage analysis for three coagulation factors clustering on chromosome 13q34: factor VII, factor X and protein Z. 5:1325-1327. 2007
The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease. 5:1250-1256. 2007
Clinical sample investigation (CSI) hematology: pinpointing the precise onset of heparin‐induced thrombocytopenia (HIT). 5:636-637. 2007
PF4‐dependent immunoassays and inferential detection of HIT antibodies. 5:232-234. 2007
Extended duration of thromboprophylaxis in acutely ill medical patients: optimizing therapy?. 5:5-11. 2007
Are placebo‐controlled trials ethical in areas where current guidelines recommend therapy? No. 4:2133-2136. 2006
The metabolic syndrome and the risk of venous thrombosis: a case–control study. 4:1914-1918. 2006
Treatment of coumarin‐associated coagulopathy: a systematic review and proposed treatment algorithms. 4:1853-1863. 2006
More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. 4:1639-1640. 2006
Clinical outcomes with unfractionated heparin or low‐molecular‐weight heparin as bridging therapy in patients on long‐term oral anticoagulants: the REGIMEN registry. 4:1246-1252. 2006
Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. 4:1432-1432. 2006
Platelet function analyzer (PFA)‐100®closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. 4:1433-1434. 2006
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. 4:1228-1236. 2006
Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. 4:1086-1094. 2006
More on: are randomized clinical trials the only truth? Not always. 4:1167-1168. 2006
Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settings. 4:759-765. 2006
Post‐thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. 4:734-742. 2006
Should vitamin K be administered when HIT is diagnosed after administration of coumarin?. 4:894-896. 2006
Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism. 4:552-556. 2006
Can evidence harm? Certainly not hemophilia treatment and community. 4:505-506. 2006
Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. 4:678-679. 2006
Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function. 4:312-319. 2006
Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis. 4:201-208. 2006
Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question. 4:16-18. 2006
No significant improvement in diagnostic specificity of an anti‐PF4/polyanion immunoassay with use of high heparin confirmatory procedure. 4:281-282. 2006
Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography. 3:2664-2670. 2005
Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. 3:2649-2655. 2005
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. 3:2479-2486. 2005
Long‐duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. 3:2121-2123. 2005
Chronic venous abnormalities in symptomatic and asymptomatic protein C deficiency. 3:1428-1431. 2005
Aspirin resistance: position paper of the Working Group on Aspirin Resistance. 3:1309-1311. 2005
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study. 3:943-948. 2005
Dose–response study of recombinant human soluble thrombomodulin (ART‐123) in the prevention of venous thromboembolism after total hip replacement. 3:962-968. 2005
High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis. 3:1094-1095. 2005
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. 3:692-694. 2005
Predictors of the post‐thrombotic syndrome during long‐term treatment of proximal deep vein thrombosis. 3:718-723. 2005
Asymptomatic thrombophilia—a family affair. 3:457-458. 2005
Hypercoagulability preceding cancer. 3:581-583. 2005
Risk of bleeding with vitamin K antagonists compared with low-molecular-weight heparin after orthopedic surgery: a rebuttal. 3:606-608. 2005
The incidence and prognostic significance of elevated cardiac troponins in patients with submassive pulmonary embolism. 3:508-513. 2005
Video laparoscopic surgery: is out-of-hospital thromboprophylaxis necessary? (vol 3, pg 216, 2004). 3:622-622. 2005
Bleeding and thrombotic problems in a patient with alpha2 plasmin inhibitor deficiency. 3:399-401. 2005
Video laparoscopic surgery: is out‐of‐hospital thromboprophylaxis necessary?. 3:216-220. 2005
Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study. 3:28-34. 2005
Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: reply to a rebuttal. 3:187-188. 2005
The multiple faces of the partial thromboplastin time APTT. 2:2250-2252. 2004
The multiple faces of the partial thromboplastin time APTT. 2:2254-2256. 2004
Measurement of soluble P‐selectin and soluble CD40 ligand in serum and plasma. 2:2067-2069. 2004
Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review. 2:1752-1759. 2004
Corrigenda. 2:1504-1504. 2004
Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents (vol 2, pg 1055, 2004). 2:1504-1504. 2004
Thrombosis and cancer: implications beyond Trousseau. 2:1261-1262. 2004
Use of different d‐dimer levels to exclude venous thromboembolism depending on clinical pretest probability. 2:1256-1260. 2004
Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. 2:1055-1057. 2004
Laboratory monitoring of low‐molecular‐weight heparin therapy. 2:1003-1003. 2004
Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency. 2:1017-1019. 2004
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. 2:743-749. 2004
Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. 2:221-227. 2004
Vitamin K antagonists and cancer: rebuttal. 2:346-379. 2004
A novel long‐acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. 2:47-53. 2004
Factors influencing therapeutic efficacy and the host immune response to helper‐dependent adenoviral gene therapy in hemophilia A mice. 2:111-118. 2004
Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. 2:42-46. 2004
Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. 1:2689-2691. 2003
Thrombosis in inherited factor VII deficiency. 1:2153-2158. 2003
Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. 1:1906-1913. 2003
A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer. 1:P1982-P1982. 2003
Effect of protein binding on the anti-FXa activity of different heparinoids in either adult or newborn plasma. 1:P2031-P2031. 2003
From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. 1:1456-1463. 2003
Influence of warfarin use on symptoms of fatigue: a randomized cross-over trial. 1:P1979-P1979. 2003
Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE). 1:OC004-OC004. 2003
The use of three hemophilia A mouse models to illustrate strain-specific differences in immune responses to FVIII protein replacement via protein infusion or adenoviral gene therapy. 1:P0041-P0041. 2003
Venous thrombosis in children. 1:1443-1455. 2003
Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. 1:881-883. 2003
Collagen platelet receptor polymorphisms integrin α2β1 C807T and GPVI Q317L and risk of ischemic stroke. 1:963-970. 2003
Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. 1:915-921. 2003
A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. 1:662-670. 2003
Choice of low molecular weight heparins. 1:598-599. 2003
Choice of low molecular weight heparins.. 1:598. 2003
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. 1:587-594. 2003
Influence of the duration of fondaparinux (Arixtra®) prophylaxis in preventing venous thromboembolism following major orthopedic surgery. 1:383-384. 2003
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. 1:41-47. 2003
Thrombus formation: direct real-time observation and digital analysis of thrombus assembly in a living mouse by confocal and widefield intravital microscopy. 1:60-68. 2003
Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. no-no.

Journal of Thrombosis and Haemostasis Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)